The drug EPI-589 (owned by Edison Pharmaceuticals) is to be trialled in Parkinson's (PD) in a proof of concept study. EPI-589 was designed to treat rare mitochondrial diseases in children and we now know that mitochondrial dysfunction is a hallmark of genetic types of Parkinson’s. This trial led by Professor Huw Morris of the Leonard Wolfson Experimental Neurology Centre at UCLH in London, will help us understand whether EPI-589 can improve mitochondrial function in neurons and if so, what benefit this has for people with Parkinson’s.

**Professor Morris will be joining us at our research update meeting to talk about mitochondrial dysfunction in PD and how certain drugs are being trialled to treat this recognised characteristic of the disease.

Book your place(s) below now.

See what some of our audience thought of our previous research meeting.